Health news
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents 13 years of age and older. Previously, the treatment was only approved…
Lybalvi® (olanzapine and samidorphan) is now available for the treatment of schizophrenia in adults and for bipolar I disorder in adults for acute treatment of manic or mixed episodes as monotherapy and as an adjunct…
The Food and Drug Administration has approved Invega Hafyera (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021